Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, treatment with VER-01, a full-spectrum cannabis extract, was evaluated over 12 weeks with extensions up to one year. The trial design, including a randomized withdrawal phase, provides a rigorous assessment of both efficacy and durability of effect. Results from this study contribute meaningful clinical evidence to guide prescribing decisions for patients who have not found adequate relief with conventional treatments.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-based treatment in chronic low back pain, a condition affecting over 500 million people globally where conventional pharmacotherapy demonstrates inadequate efficacy and safety profiles. The large sample size (820 participants) and double-blind design with extended follow-up enhance the clinical credibility of findings regarding VER-01’s efficacy and tolerability, potentially establishing a new therapeutic option for patients who fail or cannot tolerate current standard-of-care treatments. If efficacy is demonstrated, this research could reshape pain management protocols by offering an evidence-based alternative with a potentially favorable risk-benefit ratio compared to opioids and other conventional analgesics.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial of VER-01, a full-spectrum cannabis extract, addresses a genuine clinical need in chronic low back pain management where conventional pharmacotherapy often falls short due to limited efficacy or adverse effects. While the study’s size and design suggest meaningful data, clinicians should note that the abstract provided appears incomplete, leaving key efficacy and safety outcomes unclear, and the generalizability of results from a single cultivar to diverse patient populations remains an open question. Full-spectrum extracts present inherent complexity around cannabinoid and terpene ratios, which can vary batch-to-batch and may influence individual patient response unpredictably. Until the complete results are available, this work is best viewed as one piece of a growing evidence base rather than definitive guidance, but it does reinforce that well-designed trials in cannabis medicine are both feasible and necessary. If this compound demonstrates clinically meaningful pain reduction with an acceptable safety profile, it could offer a reasonable option for patients who have exhausted or cannot tolerate traditional
| |